MX2023004718A - Antigeno quimerico que comprende el dominio extracelular de pd-l1. - Google Patents

Antigeno quimerico que comprende el dominio extracelular de pd-l1.

Info

Publication number
MX2023004718A
MX2023004718A MX2023004718A MX2023004718A MX2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A MX 2023004718 A MX2023004718 A MX 2023004718A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
extracellular domain
metastasis
pharmaceutical composition
treating cancer
Prior art date
Application number
MX2023004718A
Other languages
English (en)
Inventor
Blanco Sonia Gonzalez
Pérez Vladimir Armando Besada
Diaz Yanelys Morera
Ávila Marta Ayala
Ramírez Javier Sánchez
Rodríguez Luis Ariel Espinosa
Fernández Miladys Limonta
Ayala Camila Canaán-Haden
Romero Mónica Bequet
Moya Isabel Gonzalez
COWLEY GAVILONDO (FINADO) Jorge Victor
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2023004718A publication Critical patent/MX2023004718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antígeno quimérico que comprende el dominio extracelular del ligando 1 del receptor proteico de muerte celular programada 1 (PD-L1) humano y que forma un multímero que tiene reducida la capacidad de unión a los receptores PD-1 y CD80 respecto a la forma nativa de PD-L1; la composición farmacéutica que comprende dicho antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable; uso de ese antígeno quimérico para la manufactura de un medicamento para el tratamiento del cáncer o sus metástasis; la invención también revela un método para el tratamiento del cáncer o sus metástasis en un individuo que lo necesita que se caracteriza porque se administra una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende dicho antígeno quimérico.
MX2023004718A 2020-10-22 2021-09-28 Antigeno quimerico que comprende el dominio extracelular de pd-l1. MX2023004718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2020000075A CU20200075A7 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1
PCT/CU2021/050008 WO2022083805A1 (es) 2020-10-22 2021-09-28 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Publications (1)

Publication Number Publication Date
MX2023004718A true MX2023004718A (es) 2023-05-10

Family

ID=78598633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004718A MX2023004718A (es) 2020-10-22 2021-09-28 Antigeno quimerico que comprende el dominio extracelular de pd-l1.

Country Status (10)

Country Link
US (1) US20230390369A1 (es)
EP (1) EP4234029A1 (es)
JP (1) JP2023546485A (es)
KR (1) KR20230107810A (es)
CN (1) CN116783221A (es)
AU (1) AU2021363436A1 (es)
CA (1) CA3196460A1 (es)
CU (1) CU20200075A7 (es)
MX (1) MX2023004718A (es)
WO (1) WO2022083805A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
CN105705522B (zh) 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
IL262606B2 (en) * 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
SG11201908528UA (en) 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
CA3196460A1 (en) 2022-04-28
AU2021363436A1 (en) 2023-06-01
JP2023546485A (ja) 2023-11-02
US20230390369A1 (en) 2023-12-07
CN116783221A (zh) 2023-09-19
CU20200075A7 (es) 2022-05-11
KR20230107810A (ko) 2023-07-18
WO2022083805A1 (es) 2022-04-28
EP4234029A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR20180004740A (ko) 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
US20220143009A1 (en) Combination of antibody-drug conjugate and immune checkpoint inhibitor
JPWO2020130125A1 (ja) 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP2019506428A5 (es)
KR20210063475A (ko) 암치료에 유용한 tie2 키나아제의 억제 방법
US20090149511A1 (en) Administration of an Inhibitor of HDAC and an mTOR Inhibitor
Sun et al. The IL-1 family in tumorigenesis and antitumor immunity
JPWO2016204193A1 (ja) 抗がん剤
Peng et al. CD25: A potential tumor therapeutic target
JP2019517504A5 (es)
KR20230167407A (ko) Cbl-b 억제제 화합물을 이용한 조합 요법
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
KR20200126334A (ko) 면역항암 보조제
KR20210031679A (ko) 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
JP2019508433A5 (es)
MX2023004718A (es) Antigeno quimerico que comprende el dominio extracelular de pd-l1.
US20200230247A1 (en) Combination therapies comprising targeted therapeutics
US11696936B2 (en) Treatment of cancer
US20210353749A1 (en) Guanabenz as an adjuvant for immunotherapy
CN113473989A (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
WO2023073645A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2023083868A1 (en) Tlr7 agonist and combinations for cancer treatment